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Background: In Australia, rheumatic heart disease (RHD) is almost exclusively restricted to Aboriginal Australian and
Torres Strait Islander people with children being at highest risk. International criteria for echocardiographic
diagnosis of RHD have been developed but the significance of minor heart valve abnormalities which do not reach
these criteria remains unclear. The Rheumatic Fever Follow-Up Study (RhFFUS) aims to clarify this question in
children and adolescents at high risk of RHD.
Methods/design: RhFFUS is a cohort study of Aboriginal and/or Torres Strait Islander children and adolescents
aged 8–17 years residing in 32 remote Australian communities. Cases are people with non-specific heart valve
abnormalities detected on prior screening echocardiography. Controls (two per case) are age, gender, community
and ethnicity-matched to cases and had a prior normal screening echocardiogram. Participants will have
echocardiography about 3 years after initial screening echocardiogram and enhanced surveillance for any history
suggestive of acute rheumatic fever (ARF). It will then be determined if cases are at higher risk of (1) ARF or (2)
developing progressive echocardiography-detected valve changes consistent with RHD.
The occurrence and timing of episodes of ARF will be assessed retrospectively for 5 years from the time of the
RhFFUS echocardiogram. Episodes of ARF will be identified through regional surveillance and notification databases,
carer/subject interviews, primary healthcare history reviews, and hospital separation diagnoses.
Progression of valvular abnormalities will be assessed prospectively using transthoracic echocardiography and
standardized operating and reporting procedures. Progression of valve lesions will be determined by specialist
cardiologist readers who will assess the initial screening and subsequent RhFFUS screening echocardiogram for
each participant. The readers will be blinded to the initial assessment and temporal order of the two
echocardiograms.
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Discussion: RhFFUS will determine if subtle changes on echocardiography represent the earliest changes of RHD
or mere variations of normal heart anatomy. In turn it will inform criteria to be used in determining whether
secondary antibiotic prophylaxis should be utilized in individuals with no clear history of ARF and minor
abnormalities on echocardiography. RhFFUS will also inform the ongoing debate regarding the potential role of
screening echocardiography for the detection of RHD in this setting.
Keywords: Rheumatic heart disease, Acute rheumatic fever, Screening, Aboriginal, Torres Strait Islander, Indigenous,
Diagnosis, Prevention, Australia, EchocardiographyBackground
Acute rheumatic fever (ARF) is an auto-immune condi-
tion resulting from infection with group-A streptococcus
(GAS) [1,2]. In susceptible individuals, two to three
weeks following throat [3,4] and possibly skin [5] infec-
tion, a delayed inflammatory response associated with
ARF can occur directed at the heart (carditis), brain
(chorea), joints (arthralgia/arthritis) and skin (rash).
While the effects of ARF are usually transitory, recurrent
episodes of ARF-related carditis can result in long-term
damage to heart valves called rheumatic heart disease
(RHD) [6,7]. The mitral and aortic valves are particularly
prone to this damage.
In Australia, acquisition of ARF and RHD is now al-
most exclusively restricted to the local indigenous popu-
lation comprising Aboriginal Australians and/or Torres
Strait Islander peoples. This is particularly the case for
those living in regional and remote areas of central and
northern Australia [8]. Rates of ARF and RHD in these
regions are among the highest documented in the world
[9]. RHD results in significant morbidity [10] and health
care utilization [10] and can lead to premature death [8].
Whilst the long-term priority for addressing ARF and
RHD remains identifying effective targets for primary
prevention, to date these have proven elusive [1,11].
Hence, the current emphasis remains the secondary pre-
vention of GAS infection with prophylactic antibiotics in
people with a history of ARF or known RHD [1,12,13].
This has been demonstrated to prevent recurrent ARF
and progression of RHD [14-17].
Central to the delivery of ARF/RHD secondary preven-
tion programs is the diagnosis of ARF and RHD. A diag-
nosis of ARF is classically made in accordance with the
Jones criteria based on a combination of major and
minor symptoms, signs and investigation results
[1,18,19]. Nonetheless, given the variable manifestations
of ARF, cases can be missed [20]. In high-risk popula-
tions in Australia, the Jones criteria have been modified
with the aim of improving their sensitivity [1].
Prior to the introduction of echocardiography (heart
ultrasound), diagnosis of RHD required an experienced
clinician with the requisite skill to identify and correctly
interpret findings detected on auscultation of the heart.Nonetheless it has been shown auscultation alone is nei-
ther sensitive [21] nor specific [22]. The increasing avail-
ability of more portable and affordable echocardiography
to assess heart valve morphology and function (stenosis
or regurgitation) has resulted in significant debate
regarding the diagnosis of RHD on echocardiography
alone. This particularly relates to the ability of echocar-
diography to confirm or refute a diagnosis of RHD. In
an attempt to address this issue, the World Heart Feder-
ation (WHF) recently released criteria [23] for the diag-
nosis of RHD based on both morphological and
functional findings on echocardiography. The WHF cri-
teria include a category of “Borderline” RHD, recogniz-
ing potential abnormalities on echocardiography that are
of uncertain significance.
The importance of such minor abnormalities was
highlighted by a recent Australian RHD prevalence and
echocardiography validation study. The gECHO (getting
Every Child’s Heart Okay) Study undertook echocardio-
graphic screening of 3978 high risk (Aboriginal Austra-
lian and/or Torres Strait Islander) and 1267 low risk
(non-Indigenous Australian) children across northern
and central Australia. Preliminary results revealed a
number of children with mild potential abnormalities of
doubtful significance (personal communication Graeme
Maguire). If these abnormalities are representative of the
earliest changes of RHD then offering such children
regular secondary prophylaxis may prevent disease pro-
gression. This question has been identified as a priority
for future investigation [24,25].
The Rheumatic Fever Follow-Up Study (RhFFUS) aims
to clarify the significance of minor echocardiographic
abnormalities in children and adolescents at high risk of
ARF/RHD. More specifically, it aims to determine if
Aboriginal and Torres Strait Islander children and adoles-
cents aged 8–17 years with a previous potentially abnor-
mal but non-diagnostic screening echocardiogram are
at higher risk of (1) contracting ARF or (2) progressive
echocardiography-detected changes consistent with RHD.
Hypothesis
Children from a population at increased risk of ARF and
RHD who have minor and non-specific heart valve
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likely to:
 have subsequent episodes of ARF and/or
 develop progressive echocardiographic changes
consistent with RHD
than age, gender, ethnicity and community-matched
children who had a previously normal echocardiogram.
Methods/design
Study design
RhFFUS is a cohort study of children with non-specific
mitral and/or aortic valve abnormalities detected on prior
screening echocardiography. Children will be assessed
prospectively for the development of progressive valve ab-
normalities and retrospectively for the incidence of ARF.
The comparator will be age, gender, community and
ethnicity-matched controls who have previously had a
normal screening echocardiogram (see Figure 1).
Study populations
Participants in this study will comprise a subset of chil-
dren who had an echocardiogram as part of the earlier
gECHO screening study. These participants reside inIndividuals Resid
Locatio
(4158
Potential Participants who satisfy RhFFUS  
inclusion  criteria
(3734)
Potential Cases
(137)
Potential Controls
(3597)
RhFFUS CASES
All potential cases will be 
followed-up 
(137)
RhFFUS MATCHED 
CONTROLS 
(2 per case)
(274)
Figure 1 Protocol for selection of participants for RhFFUS. “Rural locat
outside of the cities of Cairns and Darwin. “Urban locations” comprise com
Cairns and Darwin. “RhFFUS inclusion criteria” are outlined in the text. “Non
self-reported as not being Aboriginal and/or Torres Strait Islander. “Definite
congenital valvular heart disease that may generate morphologic or functio
root, mitral valve prolapse). “Case or Control” criteria are defined in the text32 remote communities across northern and central
Australia (see Figure 2).
Inclusion criteria
Children who participated in the gECHO study will be
eligible for inclusion in RhFFUS if they identify as Abori-
ginal Australian and/or Torres Strait Islander and live in
a remote location.
Exclusion criteria
Children who participated in the gECHO study will not
be eligible for inclusion in RhFFUS if they identify as
non-Indigenous Australians, live in urban locations, had
a diagnosis of definite RHD based on gECHO screening,
or had a diagnosis of congenital valvular heart disease
that may generate morphologic or functional abnormal-
ities similar to RHD (bicuspid aortic valve, dilated aortic
root, mitral valve prolapse).
Case/control definition
Cases will be children with non-specific findings on their
gECHO screening echocardiogram. More specifically,
their screening echocardiogram from gECHO must not
fulfill WHF echocardiography criteria for definite RHD
[23] and must meet one of the echocardiographic criteriaParticipants from gECHO
3 years prior
(5245)
ing in Rural 
ns
)
Individuals Residing in Urban 
Locations - excluded
(1087)
Non-Indigenous, Definite RHD, CHD, or failed to satisfy 
criteria to be Case or Control - excluded
(424)
ions” comprise those communities involved in the gECHO that are
munities involved in the gECHO study that are within the cities of
-Indigenous” refers to subjects enrolled in the gECHO project who
RHD” is defined by WHF criteria [23]. “CHD” refers to a diagnosis of
nal abnormalities similar to RHD (bicuspid aortic valve, dilated aortic
.
Figure 2 The 32 RhFFUS sites from Western Australia, the Northern Territory, and far north Queensland.
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minor echocardiographic abnormalities, criteria for cases
are more sensitive than WHF criteria for borderline RHD
[23]; 47 of the 137 cases included in RhFFUS satisfy the
criteria for borderline RHD. Controls will be children
who had a normal echocardiogram as outlined below.
Cases:
1. One or more morphologic changes of the mitral
valve (MV)* and/or aortic valve (AV)* without
pathologic mitral regurgitation (MR)* or aortic
regurgitation (AR)*; or
2. Pathologic MR* with no or one morphologic feature
of RHD* or pathologic AR* with no or one
morphologic feature of RHD* (not both); or
3. Multiple MR jets and/or multiple AR jets (in at least
two views) that do not fulfill criteria for pathologic
MR* or AR*
Note: *Criteria for morphologic changes of MV and
AV, and pathologic AR and MR as described by WHF
criteria [23].
Controls:
1. No morphologic features of RHD of the AV or MV;
and2. MR < 1 cm; and
3. No AR; and
4. No other acquired or congenital valvular heart disease
The matching process will involve stratifying all eli-
gible gECHO participants by community, gender and
age. For each identified case, the closest age-matched
control from the same community and of the same gen-
der will then be selected and assigned to the case. This
process will be repeated so that two matched controls
are assigned to each case.
Sample size
Sample size estimations are based on projected rates of
ARF based on the annual incidence of ARF in people with
known RHD (2.5%) and the background annual incidence
of ARF in 5 to 14 year old Aboriginal and Torres Strait
Islander children in the NT (0.27%) (personal communi-
cation Northern Territory ARF/RHD register) over a five
year period. Based on an assumed alpha of 0.05 and beta
of 0.1 (power of 90%) detecting a difference of one or
more episodes of ARF in 12.5% of cases and 1.35% of
controls over five years of follow-up, and using a ratio of
cases to controls of 1:2, would require a sample size
of 83 cases and 165 controls or a total number of 248
reviews. While it is apparent that carditis in the acute
setting of ARF may resolve in up to half of cases [26]
there are no clear data to inform the powering of
Table 1 Criteria for ARF, definite, probable, possible,
potential
Diagnosis Criteria
Definite ARF Australian modified Jones criteria for high risk
populations (includes echocardiographic evidence
of carditis and monoarthritis as major criteria) [1]
Probable ARF •Arthritis/arthralgia; and
•One or more of: temperature ≥ 38°C, C-reactive
protein ≥ 30 mg/L, erythrocyte sedimentation
rate ≥ 30 mm/h, prolonged P-R interval on ECG*;
and
•GAS infection**; and
•No other diagnosis [28]
Possible ARF •Arthritis/arthralgia; and
•GAS infection**; and
•No other diagnosis
Potential ARF •Arthritis/athralgia; and
•No other diagnosis
*Upper limits of normal of P-R interval are: 3–12 years, 0.16s; 12–16 years,
0.18s; 17+ years, 0.20s [1].
**GAS infection is defined as throat swab positive for GAS on culture or
serology consistent with recent GAS infection including elevated
antistreptolysin O titre and antideoxyribonuclease B antibodies as outlined in
the Australian guideline for prevention, diagnosis and management of acute
rheumatic fever and rheumatic heart disease (2nd edition) [1].
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Nonetheless, if it is assumed at most 5% of controls will
develop morphologic and function valvular changes on
echocardiography compared with 20% of those with pre-
existing non-specific changes then it would require the
follow-up of 77 cases and 154 controls to detect such a
difference with the tolerances above, a number of enrol-
ments well within the projected subject numbers.
Informed consent
Parents, carers or guardians of all identified subjects will
be informed regarding the study using local Indigenous
research staff and local language translators as required.
Written informed consent will be obtained. In addition
written assent will be obtained from subjects who are
14 years and older. Subjects who are 16 years and older,
who fulfill the criteria for mature minors [27] and who
are not living with the people who would normally be
identified as parents, carers or guardians will be able to
provide their own consent.
Enrolling participants
Potential participants will be approached with the assist-
ance of local research assistants and the local primary
health care centre. In addition, RhFFUS staff will visit
the homes of potential participants in the company of a
local health care staff member or a community-based In-
digenous Australian research assistant in order to con-
tact and enroll potential participants. If potential cases
have moved to another location since the gECHO pro-
ject, attempts will be made to ascertain their most recent
address and, if feasible, to contact and follow them up
there.
Data collection and outcomes
Outcome data for cases and controls will include ARF
incidence and the development or progression of mitral
and/or aortic valve abnormalities.
(a) ARF incidence
The occurrence and timing of episodes of ARF will
be assessed retrospectively for 5 years from the time
of the RhFFUS screening echocardiography.
Anecdotal evidence suggests that in the setting
where RhFFUS is being conducted, episodes of ARF
may be missed or not recorded owing to insufficient
diagnostic information being collected at time of
presentation to primary health care sites. Thus, in
order to increase the power of RhFFUS to detect
differences between case and controls, four
categories of ARF will be used as outcome variables
(see Table 1).
To gain a comprehensive overview of ARF episodes
a number of sources of data will be examined.These comprise: regional surveillance and
notification databases; carer/subject interviews;
primary healthcare history reviews; and hospital
separation diagnoses.
At time of enrolment an interview of the
participants and/or their carers/family will be
undertaken. Data collected will comprise:
demographics, knowledge of ARF or RHD
diagnoses, episodes suggestive of ARF (arthritis/
arthralgia), whether the participant is receiving
secondary prophylaxis, household crowding and
socioeconomic data.
A primary health care and hospital history review
will also be undertaken in a representative subset of
participants. Data collected during this review will
comprise information about potential episodes of
ARF, arthritis/arthralgia, chorea and diagnoses of
RHD. Clinical data regarding each potential episode
of ARF, based on the Australian modified Jones
criteria [1], will be collected. These data will be used
to validate the accuracy of existing register-based
ARF notifications.
(b) Progression of valvular abnormalities
Progression of valvular abnormalities will be
assessed prospectively using transthoracic
echocardiography and standardized operating and
reporting procedures already developed and refined
for the gECHO study. Briefly the echocardiogram
will be undertaken using a Vividi/e portable cardiac
Table
Echoc
Parast
2 dim
PLAX
Parast
PSAX
Apical
Apical
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standardized machine setup as outlined below. Highest frequency transducer that gives adequate
penetration,
 Colour gain set by gradually increasing until static
background noise barely appears,
 No electrocardiography (ECG) for screening studies,
 ECG for comprehensive studies,
 At least 2 second video acquisition of each view
with longer periods for detailed sweeping of
potentially abnormal valves
Studies will initially involve a screening echocardiogram
which will proceed to a comprehensive study if there is
one or more of: mitral regurgitation ≥ 10mm; any aortic
regurgitation; any other abnormal mitral or aortic valve
findings; or any other pathology present (e.g. abnormal
morphology, thickening, multiple regurgitant jets etc.).
Screening echocardiograms will incorporate the views
and assessments outlined in Table 2. Comprehensive
echocardiograms, if required, will incorporate more
detailed information based on the abnormalities detected
on the screening study and will be undertaken using the
views and assessments outlined in Table 3. All echocar-
diograms will be carried out by trained, accredited and
practicing echocardiographers.
Progression of a valve lesion will be defined as one or
more of: development of any morphologic or function
abnormality in a control subject; development of a new
functional or morphologic abnormality in a case; or pro-
gression of severity of a functional valve lesion (regurgi-
tation/stenosis) based on standard severity criteria [29].
Progression of valve lesions will be determined by
specialist cardiologist readers who will be provided with
the initial gECHO screening and subsequent RhFFUS
screening echocardiogram for each participant. Studies2 View and assessments required for RhFFUS screening
ardiographic view
ernal long axis (PLAX)
ensional (2D)
Mitral and aortic valves to assess
AMVL and posterior mitral valve
AMVL - ensure view is on axis a
parallel with the IVS
PMVL - ensure view is on axis an
from the measurements.
colour Doppler Colour Doppler to view the mitr
and inferior sweeps
ernal short axis (PSAX) 2D View of the mitral and aortic val
colour Doppler Colour Doppler to view the mitr
and inferior sweeps
2D Apical 4/5 chamber view of mit
colour Doppler Colour Doppler to view the mitrwill be read and assessed individually and then in pairs.
The readers will be blinded to the initial gECHO assess-
ment and temporal order of the two echocardiograms.
Reporting will use a standardized reporting template.Blinding
In order to limit any potential for information bias in this
study only the study coordinator at each site will know
whether a participant is a case or control. Thus the sono-
grapher carrying out the echocardiogram, the researchers
involved in reviewing each participant’s medical history
and the cardiologist assessing the echocardiogram will
be blinded to the participant’s status as case or control.Data management
All data collected on paper-based forms (participant/
carer/family interviews and medical history reviews) will
be stored under numerical code in a locked filing cabinet
in the RhFFUS study coordinator’s office. Only research
personnel will have access to these records.
Reports from the echocardiogram readers will be
received in electronic format and will be saved in a
password-protected folder on the study coordinator’s
computer.
Research staff will transfer the information from both
paper forms and electronic echocardiogram reports to an
Access database (Microsoft Office Access 2007, Microsoft
Corporation, Redmond, Washington, USA) that will be
password-protected. De-identified data will be analysed
using STATA version 12 (StataCorp, College Station,
Tex, USA).
Any information collected will be strictly confidential
and no identifying information will be published or dis-
seminated upon completion of the study. Data will be
stored for at least 5 years as per Australian National
Health and Medical Research Council guidelines [30].echocardiogram
Assessment
the morphology of these valves
leaflet (PMVL) thickness
nd measure the thickest point of AMVL in late diastole when AMVL
d measure the thickest point of the PMVL mid diastole, exclude chordae
al and aortic valves for evidence of regurgitation, include lateral
ves to assess morphology
al and aortic valves for evidence of regurgitation, include lateral
ral and aortic valves for morphology
al and aortic valves for evidence of regurgitation
Table 3 Requirement, view and assessments required for RhFFUS comprehensive echocardiogram
Potential abnormality View and Assessment
All comprehensive studies PLAX 2D assessment of:
- left ventricular chamber dimensions at the level of the mitral valve leaflet tips
(interventricular septum thickness, left ventricular end-diastolic & systolic dimensions,
left ventricular posterior wall thickness)
- aorta and left atrium diameter at the aortic cusp level
Dependent on the presence of potential
mitral or aortic valve disease
Standardized additional studies including routine acquisition of colour, continuous
and pulse wave Doppler measurements
Any other pathology As per routine clinical protocols
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The primary analysis will be based on univariate analysis
comparing cases and matched controls. This will include
a χ2 analysis comparing the number of children with an
episode of ARF (stratified by definite, probable, possible
and potential (see Table 1)) during the period of follow-
up and those who have demonstrated progression of a
valve lesion (see above). More detailed analysis will in-
clude survival analysis comparing the timing of first epi-
sode of ARF to address potential loss of follow-up and
Poisson regression for the rate of ARF to address the
potential occurrence of more than one episode of ARF
occurring in any one individual and a variable period of
follow-up. Multivariate techniques (logistic regression
and Cox proportional hazard) will be utilized if the
matching of cases and controls is not successful and to
addresses subsequently identified covariates including
the possibility of concomitant prophylactic antibiotics.
Ethics
RhFFUS has been approved by human ethics research
committees in each of the jurisdictions where it will
be undertaken. Approval has been granted by the fol-
lowing committees: Darling Downs – West Moreton
(Toowoomba and Darling Downs) Health Service Dis-
trict Human Research Ethics Committee (Queensland)
(HREC/11/QTDD/10), James Cook University Human
Research Ethics Committee (Queensland)(H4136), Central
Australian Human Research Ethics Committee (Northern
Territory)(HREC-12-35), the Human Research Ethics
Committee of Northern Territory department of Health
and Menzies School of Health Research (Northern
Territory)(HREC-2011-1564), the WA Country Health
Service Research Ethics Committee (Western Australia)
(2011:31), the Western Australian Aboriginal Health
Ethics Committee (Western Australia)(371-10/11), the
University of Western Australia Human Research Ethics
Committee (Western Australia)(RA/4/1/5313).
Funding
The RhFFUS project is funded by the Australian
Government through a grant from the National Healthand Medical Research Council (NHMRC Project Grant
Application 1005951).Discussion
The results of RhFFUS will be integral in informing the
future response to ARF and RHD in Australia. In par-
ticular, RhFFUS will clarify the criteria to be used in de-
termining whether secondary antibiotic prophylaxis
should be prescribed in individuals with no clear history
of ARF but minor potential abnormalities detected on
echocardiography suggestive, but not diagnostic, of
RHD. RhFFUS will also help inform the ongoing debate
regarding the potential role of screening echocardiog-
raphy in this setting. In particular, it will allow clinicians
to understand the significance of subtle changes on
echocardiography and to determine whether these repre-
sent the earliest changes of RHD or are merely variations
of normal heart anatomy.
At present, minor non-diagnostic changes of heart
morphology are the commonest silent findings when
echocardiography is undertaken in otherwise well chil-
dren. Whether such changes indicate a large burden of
minor and undiagnosed RHD that would benefit from
secondary prophylaxis or incidental normal variants will
be essential in providing an evidence-based rationale for
echocardiographic screening in populations at elevated
risk of RHD.
Finally this project will continue to support the devel-
opment of research capacity in northern and remote
Australia and of Aboriginal and Torres Strait Islander
people. It will enable us to ask and answer health-related
questions which are relevant and a priority in informing
the response to addressing the disparity in disease bur-
den and health outcome between Indigenous and non-
Indigenous Australians.
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gECHO: Getting Every Child’s Heart Okay study; MR: Mitral regurgitation;
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